NPPA Fixes Retail Prices for 28 Drug Formulations Including Dapagliflozin, Telmisartan, Amoxycillin, Details
New Delhi: Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has fixed retail prices for 28 essential drug formulations including a wide range of combination drugs commonly prescribed for diabetes, hypertension, allergies, infections, and gastrointestinal conditions.
The prices, determined under the Drugs (Prices Control) Order, 2013 (DPCO), are exclusive of Goods and Services Tax (GST) and apply to specific manufacturers and marketing companies that applied under Form-I for price fixation.
The formulations include combinations such as Amlodipine with Valsartan, Dapagliflozin with Sitagliptin and Metformin, Empagliflozin with Linagliptin or Sitagliptin and Metformin, Telmisartan-based triple combinations, Levocetirizine with Montelukast, and Amoxycillin with Clavulanate, among others.
Some of the notable price approvals include Windlas Biotech / Alembic Pharmaceuticals' Amlodipine and Valsartan Tablets, Exemed Pharmaceuticals/ Corona Remedies' Empagliflozin, Linagliptin and Metformin Hydrochloride Extended Release Tablets, Ravenbhel Healthcare/Cipla's Levocetirizine Hydrochloride and Montelukast Syrup, Ajanta Pharma/ Sun Pharma Laboratories' Metoprolol succinate Extended Release, Amlodipine and Telmisartan Tablets, Pure and Cure Healthcare/ Dr. Reddy’s Laboratories' Mefenamic acid and Paracetamol Tablets, and others.
This came in exercise of the powers conferred by paragraphs 5, 11, and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (NPPA) has fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer and marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Sl. No. | Medicine | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1 | Amlodipine & Valsartan Tablets | Each film coated tablet contains: Amlodipine besylate IP eq. to Amlodipine 5 mg Valsartan IP 80 mg | 1 Tablet | M/s Windlas Biotech Ltd./ M/s Alembic Pharmaceuticals Ltd. | 7.41 |
2 | Dapagliflozin, Sitagliptin & Metformin Hydrochloride (Extended Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP Eq. to Dapagliflozin 10 mg Sitagliptin Phosphate Monohydrate IP Eq. to Sitagliptin 100 mg Metformin Hydrochloride IP 500 mg (As extended release form) | 1 Tablet | M/s Windlas Biotech Ltd. / M/s Jagsonpal Pharmaceuticals Ltd. | 18.18 |
3 | Empagliflozin, Linagliptin & Metformin Hydrochloride Extended Release Tablets | Each film coated bilayer tablet contains: Empagliflozin 10mg Linagliptin 5 mg Metformin Hydrochloride (Extended Release) IP 1000 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Corona Remedies Pvt. Ltd. | 29.21 |
4 | Empagliflozin, Sitagliptin and Metformin Hydrochloride Extended Release Tablets | Each film coated bilayer tablet contains: Empagliflozin 25 mg Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 100 mg, Metformin Hydrochloride (As Extended Release) IP 1000 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Alembic Pharmaceuticals Ltd. | 25.00 |
5 | Levocetirizine Hydrochloride & Montelukast Syrup | Each 5 ml contains: Levocetirizine Hydrochloride IP 2.5 mg Montelukast Sodium IP eq. to Montelukast 5 mg | 1 ml | M/s Ravenbhel Healthcare Pvt. Ltd. M/s Cipla Ltd. | 1.88 |
6 | Linagliptin & Metformin Hydrochloride (ER) Tablets | Each film coated bilayered tablet contains: Linagliptin 5 mg Metformin Hydrochloride IP 500 mg (As extended-release form) | 1 Tablet | M/s Mascot Health Series Pvt. Ltd./ M/s Primus Remedies Pvt. Ltd. | 10.09 |
7 | Metoprolol succinate Extended Release, Amlodipine & Telmisartan Tablets | Each film coated bilayered tablet contains: Metoprolol succinate IP 23.75 mg eq. to Metoprolol Tartrate 25 mg (As extended release) Amlodipine Besilate IP eq to Amlodipine 5 mg Telmisartan IP 40 mg | 1 Tablet | M/s Ajanta Pharma Ltd./ M/s Sun Pharma Laboratories Ltd. | 13.01 |
8 | Mefenamic acid & Paracetamol Tablets | Each uncoated tablet contains: Mefenamic Acid IP 500 mg Paracetamol IP 325 mg | 1 Tablet | M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Dr. Reddy’s Laboratories Ltd. | 3.91 |
9 | S (-) Pantoprazole for Injection (Lyophilized) | Each vial contains: S (-) Pantoprazole Sodium equivalent to S (-) Pantoprazole 20mg | 1 Vial | M/s Gufic Biosciences Ltd. | 118.39 |
Sl. No. | Medicine | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
10 | S (-) Pantoprazole for Injection (Lyophilized) | Each vial contains: S (-) Pantoprazole Sodium equivalent to S (-) Pantoprazole 20mg | 1 Vial | M/s Gufic Biosciences Ltd./ M/s Tyykem Pvt. Ltd. | 118.39 |
11 | Paracetamol & Caffeine Tablets | Each uncoated tablet contains: Paracetamol IP 650 mg Caffeine IP 50 mg | 1 Tablet | M/s Psychotropics India Ltd. | 4.01 |
12 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50 mg, Glimepiride IP 1 mg, Metformin Hydrochloride IP 1000 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Ipca Laboratories Ltd. | 11.18 |
13 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50 mg, Glimepiride IP 2 mg, Metformin Hydrochloride IP 1000 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Ipca Laboratories Ltd. | 12.78 |
14 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50 mg, Glimepiride IP 1 mg, Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Ipca Laboratories Ltd. | 13.24 |
15 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50 mg, Glimepiride IP 2 mg, Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Ipca Laboratories Ltd. | 14.92 |
16 | Alginate Raft- forming Oral Suspension BP | Each 5ml contains: Sodium Alginate IP 250 mg Sodium Bicarbonate IP 133.5 mg Calcium Carbonate IP 80 mg | 1 ml | M/s Skymap Pharmaceuticals Pvt. Ltd. M/s German Remedies Pharmaceuticals Pvt. Ltd. | 0.95 |
17 | Telmisartan & Amlodipine Tablets | Each uncoated bilayered tablet contains: Telmisartan IP 40 mg Amlodipine Besilate IP 5 mg | 1 Tablet | M/s Swiss Garnier Life Sciences/ M/s SRK Puremed LLP | 7.14 |
18 | Telmisartan & Amlodipine Tablets | Each uncoated bilayered tablet contains: Telmisartan IP 80 mg Amlodipine Besilate Equivalent to Amlodipine IP 5 mg | 1 Tablet | M/s Swiss Garnier Life Sciences/ M/s SRK Puremed LLP | 9.82 |
19 | Telmisartan & Chlorthalidone Tablets | Each uncoated tablet contains: Telmisartan IP 40 mg Chlorthalidone IP 12.5 mg | 1 Tablet | M/s Swiss Garnier Life Sciences/ M/s SRK Puremed LLP | 8.93 |
20 | Telmisartan & Chlorthalidone Tablets | Each uncoated tablet contains: Telmisartan IP 80 mg Chlorthalidone IP 12.5 mg | 1 Tablet | M/s Swiss Garnier Life Sciences/ M/s SRK Puremed LLP | 11.16 |
21 | Telmisartan, Cilnidipine and Metoprolol | Each film coated bilayered tablet contains: Telmisartan IP 40 mg Cilnidipine IP 10 mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd./ M/s Aristo Pharmaceuticals Pvt. Ltd. | 11.39 |
Sl. No. | Medicine | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
Succinate (ER) Tablets | Metoprolol Succinate IP 23.75 mg eq. to Metoprolol Tartrate (As extended release) 25 mg | ||||
22 | Telmisartan, Cilnidipine and Metoprolol Succinate (ER) Tablets | Each film coated bilayered tablet contains: Telmisartan IP 40 mg Cilnidipine IP 10 mg Metoprolol Succinate IP 47.50 mg eq. to Metoprolol Tartrate (As extended release) 50 mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd./ M/s Aristo Pharmaceuticals Pvt. Ltd. | 14.35 |
23 | Telmisartan & Hydrochlorothiazide Tablets | Each uncoated tablet contains: Telmisartan IP 80 mg Hydrochlorothiazide IP 12.5 mg | 1 Tablet | M/s Unison Pharmaceuticals Pvt. Ltd. | 14.00 |
24 | Telmisartan & Hydrochlorothiazide Tablets | Each uncoated bilayered tablet contains: Telmisartan IP 80 mg Hydrochlorothiazide IP 12.5 mg | 1 Tablet | M/s Swiss Garnier Life Sciences/ M/s SRK Puremed LLP | 10.29 |
25 | Theophylline Anhydrous (SR) & Montelukast Sodium Tablets | Each Film coated Tablet Contains: Theophylline (Anhydrous) IP 400 mg (as sustained release) Montelukast Sodium IP Equivalent to Montelukast 10 mg | 1 Tablet | M/s East African (I) Overseas/ M/s Zydus Healthcare Ltd. | 13.78 |
26 | Amoxycillin & Potassium Clavulanate tablets | Each film coated tablet contains: Amoxycillin Trihydrate IP Equivalent to Amoxycillin 875 mg Potassium Clavulanate Diluted IP Equivalent to Clavulanic Acid 125 mg | 1 Tablet | M/s Alps Communication Pvt. Ltd./ M/s Indoco Remedies Ltd. | 42.84 |
27 | Teneligliptin, Dapagliflozin, Metformin (Sustained Release) Tablets | Each film-coated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate IP eq. to Teneligliptin 20 mg, Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10 mg, Metformin Hydrochloride I.P 1000 mg (As Sustained Release) | 1 Tablet | M/s Synokem Lifesciences Pvt. Ltd / M/s Glenmark Pharmaceuticals Ltd. | 13.39 |
28 | Povidone Iodine alcoholic prep solution 10% w/v | Povidone Iodine IP 10.0% w/v (available Iodine 1.0% w/v) Ethanol IP 30% v/v | 1 ml | M/s G.S. Pharmbutor Pvt. Ltd./ M/s Win-Medicare Pvt. Ltd. | 1.14 |
The notification further added:
(a) The manufacturer of above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer and Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
To view the official notice, click the link below:
- nppa
- retail price fixation
- essential medicines
- levocetirizine montelukast
- amoxycillin clavulanate
- mefenamic acid paracetamol
- telmisartan combinations
- paracetamol caffeine
- dr reddy’s laboratories
- sun pharma
- alembic pharmaceuticals
- ipca laboratories
- drug pricing regulation
- drug formulations
- amlodipine
- Valsartan
- dapaglifozin
- Sitagliptin
- Metformin
- empagliflozin
- Linagliptin
- teneligliptin
- drug price list
Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.